))
Episode 5: Three Questions with Bob Coughlin from MassBio
Manage episode 337444529 series 3381207
Conteúdo fornecido por Gunnar Esiason. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Gunnar Esiason ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Gunnar Esiason and Bob Coughlin, the former CEO of MassBio, talk about the state of the biotechnology industry in the background of the COVID-19 pandemic. Bob shares why the biotechnology trade association is important for biotech companies in Massachusetts, before getting into the industry's reputation and how he thinks the pandemic will impact the way people view drug makers. Gunnar talks about why he thinks patients should be able to own clinical trial data, why clinical trials are not accessible enough for diverse patient populations, and how patients should be included throughout the drug development process.
To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy
Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
23 episódios
Compartilhar
